{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:08:08Z","timestamp":1790003288839,"version":"4.0.1"},"reference-count":175,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"DOI":"10.1007\/s40256-026-00828-2","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:46:47Z","timestamp":1790002007000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beta-Blockers for the Treatment of Arrhythmias: Which Drug for Which Arrhythmia? A State-of-the-Art Narrative Review"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8314-4859","authenticated-orcid":false,"given":"Lucian","family":"Muresan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Cismaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan Lucian","family":"Popa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radu","family":"Rosu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Gusetu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihai","family":"Puiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razvan Olimpiu","family":"Mada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crina","family":"Muresan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Le Bouar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serban","family":"Schiau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charline","family":"Daval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael Pedro","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"issue":"6","key":"828_CR1","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/MJT.0b013e318188bdca","volume":"15","author":"WH Frishman","year":"2008","unstructured":"Frishman WH. Beta 1-Adrenergic blockers: a 50-year historical perspective. Am J Ther. 2008;15(6):565\u201376. https:\/\/doi.org\/10.1097\/MJT.0b013e318188bdca.","journal-title":"Am J Ther"},{"issue":"2","key":"828_CR2","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1177\/0269881115612236","volume":"30","author":"SA Steenen","year":"2016","unstructured":"Steenen SA, van Wijk AJ, van der Heijden GJ, et al. Propranolol for the treatment of anxiety disorders: systematic review and meta-analysis. J Psychopharmacol. 2016;30(2):128\u201339. https:\/\/doi.org\/10.1177\/0269881115612236.","journal-title":"J Psychopharmacol"},{"issue":"7342","key":"828_CR3","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S0140-6736(64)91275-9","volume":"1","author":"JW Black","year":"1964","unstructured":"Black JW, Crowther AF, Shanks RG, et al. A new adrenergic betareceptor antagonist. Lancet. 1964;1(7342):1080\u20131. https:\/\/doi.org\/10.1016\/S0140-6736(64)91275-9.","journal-title":"Lancet"},{"issue":"2","key":"828_CR4","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/0002-8703(80)90112-X","volume":"100","author":"JM Cruickshank","year":"1980","unstructured":"Cruickshank JM. The clinical importance of cardioselectivity and lipophilicity in beta blockers. Am Heart J. 1980;100(2):160\u201378. https:\/\/doi.org\/10.1016\/0002-8703(80)90112-X.","journal-title":"Am Heart J"},{"issue":"1","key":"828_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ccep.2010.10.012","volume":"3","author":"C Antzelevitch","year":"2011","unstructured":"Antzelevitch C, Burashnikov A. Overview of basic mechanisms of cardiac arrhythmia. Card Electrophysiol Clin. 2011;3(1):23\u201345. https:\/\/doi.org\/10.1016\/j.ccep.2010.10.012.","journal-title":"Card Electrophysiol Clin"},{"issue":"8","key":"828_CR6","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jacc.2012.07.074","volume":"61","author":"B Olshansky","year":"2013","unstructured":"Olshansky B, Sullivan RM. Inappropriate sinus tachycardia. J Am Coll Cardiol. 2013;61(8):793\u2013801. https:\/\/doi.org\/10.1016\/j.jacc.2012.07.074.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"828_CR7","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1016\/j.hrthm.2015.03.029","volume":"12","author":"RS Sheldon","year":"2015","unstructured":"Sheldon RS, Grubb BP 2nd, Olshansky B, et al. 2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm. 2015;12(6):e41-63. https:\/\/doi.org\/10.1016\/j.hrthm.2015.03.029.","journal-title":"Heart Rhythm"},{"issue":"5","key":"828_CR8","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/eurheartj\/ehz467","volume":"41","author":"J Brugada","year":"2020","unstructured":"Brugada J, Katritsis DG, Arbelo E, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardia. The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(5):655\u2013720. https:\/\/doi.org\/10.1093\/eurheartj\/ehz467.","journal-title":"Eur Heart J"},{"issue":"1","key":"828_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/archinte.1969.00300110003001","volume":"123","author":"ED Frohlich","year":"1969","unstructured":"Frohlich ED, Tarazi RC, Dustan HP. Hyperdynamic beta-adrenergic circulatory state. Increased beta-receptor responsiveness. Arch Intern Med. 1969;123(1):1\u20137. https:\/\/doi.org\/10.1001\/archinte.1969.00300110003001.","journal-title":"Arch Intern Med"},{"issue":"2","key":"828_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1023\/A:1007784109255","volume":"13","author":"C Smith","year":"1999","unstructured":"Smith C, Teitler M. Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors. Cardiovasc Drugs Ther. 1999;13(2):123\u20136. https:\/\/doi.org\/10.1023\/A:1007784109255.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"15","key":"828_CR11","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.jacc.2012.06.031","volume":"60","author":"R Cappato","year":"2012","unstructured":"Cappato R, Castelvecchio S, Ricci C, et al. Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation. J Am Coll Cardiol. 2012;60(15):1323\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2012.06.031.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"828_CR12","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1097\/SHK.0000000000002576","volume":"63","author":"S Lu","year":"2025","unstructured":"Lu S, Kattan E, Pan C, et al. Very early use of esmolol in hyperkinetic septic shock patients with persistent tachycardia: a randomized controlled pilot study. Shock. 2025;63(6):870\u20137. https:\/\/doi.org\/10.1097\/SHK.0000000000002576.","journal-title":"Shock"},{"issue":"9","key":"828_CR13","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1161\/CIRCULATIONAHA.108.846501","volume":"120","author":"SR Raj","year":"2009","unstructured":"Raj SR, Black BK, Biaggioni I, et al. Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: less is more. Circulation. 2009;120(9):725\u201334. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.846501.","journal-title":"Circulation"},{"issue":"6","key":"828_CR14","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/j.1540-8159.2006.00413.x","volume":"29","author":"KC Roberts-Thomson","year":"2006","unstructured":"Roberts-Thomson KC, Kistler PM, Kalman JM. Focal atrial tachycardia I: clinical features, diagnosis, mechanisms, and anatomic location. Pacing Clin Electrophysiol PACE. 2006;29(6):643\u201352. https:\/\/doi.org\/10.1111\/j.1540-8159.2006.00413.x.","journal-title":"Pacing Clin Electrophysiol PACE."},{"issue":"3","key":"828_CR15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/hrt.2008.143552","volume":"96","author":"R Rosso","year":"2010","unstructured":"Rosso R, Kistler PM. Focal atrial tachycardia. Heart. 2010;96(3):181\u20135. https:\/\/doi.org\/10.1136\/hrt.2008.143552.","journal-title":"Heart"},{"issue":"6","key":"828_CR16","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2165\/11631590-000000000-00000","volume":"51","author":"DB Wiest","year":"2012","unstructured":"Wiest DB, Haney JS. Clinical pharmacokinetics and therapeutic efficacy of esmolol. Clin Pharmacokinet. 2012;51(6):347\u201356. https:\/\/doi.org\/10.2165\/11631590-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"issue":"24","key":"828_CR17","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJM199006143222405","volume":"322","author":"JA Kastor","year":"1990","unstructured":"Kastor JA. Multifocal atrial tachycardia. N Engl J Med. 1990;322(24):1713\u20137. https:\/\/doi.org\/10.1056\/NEJM199006143222405.","journal-title":"N Engl J Med"},{"issue":"4","key":"828_CR18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0002-9343(88)80088-3","volume":"85","author":"E Arsura","year":"1988","unstructured":"Arsura E, Lefkin AS, Scher DL, et al. A randomized, double-blind, placebo-controlled study of verapamil and metoprolol in treatment of multifocal atrial tachycardia. Am J Med. 1988;85(4):519\u201324. https:\/\/doi.org\/10.1016\/S0002-9343(88)80088-3.","journal-title":"Am J Med"},{"issue":"5","key":"828_CR19","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1080\/03007995.2026.2692171","volume":"42","author":"E Perger","year":"2026","unstructured":"Perger E, Luppi F, Faverio P, et al. Therapeutic use of cardioselective beta-blockers for patients with chronic obstructive pulmonary disease: a review of current clinical evidence. Curr Med Res Opin. 2026;42(5):879\u201397. https:\/\/doi.org\/10.1080\/03007995.2026.2692171.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"828_CR20","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373\u2013498. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa612.","journal-title":"Eur Heart J"},{"issue":"10046","key":"828_CR21","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/S0140-6736(16)31258-2","volume":"388","author":"IC Van Gelder","year":"2016","unstructured":"Van Gelder IC, Rienstra M, Crijns HJ, et al. Rate control in atrial fibrillation. Lancet. 2016;388(10046):818\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(16)31258-2.","journal-title":"Lancet"},{"issue":"15","key":"828_CR22","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa1001337","volume":"362","author":"IC Van Gelder","year":"2010","unstructured":"Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362(15):1363\u201373. https:\/\/doi.org\/10.1056\/NEJMoa1001337.","journal-title":"N Engl J Med"},{"issue":"23","key":"828_CR23","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1056\/NEJMoa021328","volume":"347","author":"DG Wyse","year":"2002","unstructured":"Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825\u201333. https:\/\/doi.org\/10.1056\/NEJMoa021328.","journal-title":"N Engl J Med"},{"issue":"1","key":"828_CR24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jjcc.2013.02.010","volume":"62","author":"T Yamashita","year":"2013","unstructured":"Yamashita T, Inoue H. Heart rate-reducing effects of bisoprolol in Japanese patients with chronic atrial fibrillation: results of the MAIN-AF study. J Cardiol. 2013;62(1):50\u20137. https:\/\/doi.org\/10.1016\/j.jjcc.2013.02.010.","journal-title":"J Cardiol"},{"issue":"24","key":"828_CR25","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1016\/j.jacc.2017.04.001","volume":"69","author":"D Kotecha","year":"2017","unstructured":"Kotecha D, Flather MD, Altman DG, et al. Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure. J Am Coll Cardiol. 2017;69(24):2885\u201396. https:\/\/doi.org\/10.1016\/j.jacc.2017.04.001.","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"828_CR26","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","volume":"334","author":"M Packer","year":"1996","unstructured":"Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334(21):1349\u201355. https:\/\/doi.org\/10.1056\/NEJM199605233342101.","journal-title":"N Engl J Med"},{"issue":"9961","key":"828_CR27","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1016\/S0140-6736(14)61373-8","volume":"384","author":"D Kotecha","year":"2014","unstructured":"Kotecha D, Holmes J, Krum H, et al. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet. 2014;384(9961):2235\u201343. https:\/\/doi.org\/10.1016\/S0140-6736(14)61373-8.","journal-title":"Lancet"},{"issue":"4","key":"828_CR28","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1253\/circj.CJ-12-1618","volume":"77","author":"R Nagai","year":"2013","unstructured":"Nagai R, Kinugawa K, Inoue H, et al. Urgent management of rapid heart rate in patients with atrial fibrillation\/flutter and left ventricular dysfunction: comparison of the ultra-short-acting beta1-selective blocker landiolol with digoxin (J-Land Study). Circ J. 2013;77(4):908\u201316. https:\/\/doi.org\/10.1253\/circj.CJ-12-1618.","journal-title":"Circ J"},{"issue":"3","key":"828_CR29","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","volume":"26","author":"MD Flather","year":"2005","unstructured":"Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215\u201325. https:\/\/doi.org\/10.1093\/eurheartj\/ehi115.","journal-title":"Eur Heart J"},{"key":"828_CR30","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11936-022-00970-5","volume":"24","author":"L Muresan","year":"2022","unstructured":"Muresan L, Rosu R, Cismaru G, et al. Nebivolol for the treatment of arrhythmias: a narrative review. Curr Treat Options Cardiovasc Med. 2022;24:231\u201343. https:\/\/doi.org\/10.1007\/s11936-022-00970-5.","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"828_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h4451","volume":"351","author":"OJ Ziff","year":"2015","unstructured":"Ziff OJ, Lane DA, Samra M, et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ. 2015;351:h4451. https:\/\/doi.org\/10.1136\/bmj.h4451.","journal-title":"BMJ"},{"issue":"14","key":"828_CR32","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","volume":"383","author":"P Kirchhof","year":"2020","unstructured":"Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020;383(14):1305\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2019422.","journal-title":"N Engl J Med"},{"issue":"23","key":"828_CR33","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa021375","volume":"347","author":"IC Van Gelder","year":"2002","unstructured":"Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347(23):1834\u201340. https:\/\/doi.org\/10.1056\/NEJMoa021375.","journal-title":"N Engl J Med"},{"key":"828_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005049.pub4","author":"C Lafuente-Lafuente","year":"2015","unstructured":"Lafuente-Lafuente C, Valembois L, Bergmann JF, et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2015. https:\/\/doi.org\/10.1002\/14651858.CD005049.pub4.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"828_CR35","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S0735-1097(00)00693-8","volume":"36","author":"V Kuhlkamp","year":"2000","unstructured":"Kuhlkamp V, Schirdewan A, Stangl K, et al. Use of metoprolol CR\/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2000;36(1):139\u201346. https:\/\/doi.org\/10.1016\/S0735-1097(00)00693-8.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"828_CR36","doi-asserted-by":"publisher","first-page":"CD013438","DOI":"10.1002\/14651858.CD013438","volume":"9","author":"H Blessberger","year":"2019","unstructured":"Blessberger H, Kammler J, Domanovits H, et al. Perioperative beta-blockers for preventing surgery-related mortality and morbidity. Cochrane Database Syst Rev. 2019;9(9):CD013438. https:\/\/doi.org\/10.1002\/14651858.CD013438.","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 1","key":"828_CR37","doi-asserted-by":"publisher","first-page":"S304","DOI":"10.1111\/jth.12974","volume":"13","author":"A Bessissow","year":"2015","unstructured":"Bessissow A, Khan J, Devereaux PJ, et al. Postoperative atrial fibrillation in non-cardiac and cardiac surgery: an overview. J Thromb Haemost JTH. 2015;13(Suppl 1):S304\u201312. https:\/\/doi.org\/10.1111\/jth.12974.","journal-title":"J Thromb Haemost JTH."},{"issue":"1","key":"828_CR38","doi-asserted-by":"publisher","first-page":"CD003611","DOI":"10.1002\/14651858.CD003611.pub3","volume":"2013","author":"KA Arsenault","year":"2013","unstructured":"Arsenault KA, Yusuf AM, Crystal E, et al. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev. 2013;2013(1):CD003611. https:\/\/doi.org\/10.1002\/14651858.CD003611.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"828_CR39","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.hrthm.2007.04.022","volume":"4","author":"M Haghjoo","year":"2007","unstructured":"Haghjoo M, Saravi M, Hashemi MJ, et al. Optimal beta-blocker for prevention of atrial fibrillation after on-pump coronary artery bypass graft surgery: carvedilol versus metoprolol. Heart Rhythm. 2007;4(9):1170\u20134. https:\/\/doi.org\/10.1016\/j.hrthm.2007.04.022.","journal-title":"Heart Rhythm"},{"issue":"4","key":"828_CR40","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1161\/CIRCEP.109.871665","volume":"2","author":"FJ Perez","year":"2009","unstructured":"Perez FJ, Schubert CM, Parvez B, et al. Long-term outcomes after catheter ablation of cavo-tricuspid isthmus dependent atrial flutter: a meta-analysis. Circ Arrhythm Electrophysiol. 2009;2(4):393\u2013401. https:\/\/doi.org\/10.1161\/CIRCEP.109.871665.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"13","key":"828_CR41","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1016\/j.jacc.2015.08.856","volume":"67","author":"RL Page","year":"2016","unstructured":"Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC\/AHA\/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2016;67(13):e27\u2013115. https:\/\/doi.org\/10.1016\/j.jacc.2015.08.856.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"828_CR42","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/0735-1097(95)00286-5","volume":"26","author":"SH Hohnloser","year":"1995","unstructured":"Hohnloser SH, van de Loo A, Baedeker F. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. J Am Coll Cardiol. 1995;26(4):852\u20138. https:\/\/doi.org\/10.1016\/0735-1097(95)00286-5.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"828_CR43","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1136\/heart.90.1.59","volume":"90","author":"E Bertaglia","year":"2004","unstructured":"Bertaglia E, Zoppo F, Bonso A, et al. Long term follow up of radiofrequency catheter ablation of atrial flutter: clinical course and predictors of atrial fibrillation occurrence. Heart. 2004;90(1):59\u201363. https:\/\/doi.org\/10.1136\/heart.90.1.59.","journal-title":"Heart"},{"issue":"1","key":"828_CR44","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S0735-1097(97)00422-1","volume":"31","author":"LA Orejarena","year":"1998","unstructured":"Orejarena LA, Vidaillet H Jr., DeStefano F, et al. Paroxysmal supraventricular tachycardia in the general population. J Am Coll Cardiol. 1998;31(1):150\u20137. https:\/\/doi.org\/10.1016\/S0735-1097(97)00422-1.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"828_CR45","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/MEJ.0b013e3283400ba2","volume":"18","author":"B Delaney","year":"2011","unstructured":"Delaney B, Loy J, Kelly AM. The relative efficacy of adenosine versus verapamil for the treatment of stable paroxysmal supraventricular tachycardia in adults: a meta-analysis. Eur J Emerg Med. 2011;18(3):148\u201352. https:\/\/doi.org\/10.1097\/MEJ.0b013e3283400ba2.","journal-title":"Eur J Emerg Med"},{"issue":"5","key":"828_CR46","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/0002-8703(85)90185-1","volume":"110","author":"J Abrams","year":"1985","unstructured":"Abrams J, Allen J, Allin D, et al. Efficacy and safety of esmolol vs propranolol in the treatment of supraventricular tachyarrhythmias: a multicenter double-blind clinical trial. Am Heart J. 1985;110(5):913\u201322. https:\/\/doi.org\/10.1016\/0002-8703(85)90185-1.","journal-title":"Am Heart J"},{"issue":"3","key":"828_CR47","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1093\/europace\/euw301","volume":"19","author":"DG Katritsis","year":"2017","unstructured":"Katritsis DG, Boriani G, Cosio FG, et al. European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE). Europace. 2017;19(3):465\u2013511. https:\/\/doi.org\/10.1093\/europace\/euw301.","journal-title":"Europace"},{"issue":"1","key":"828_CR48","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/00005344-198201000-00003","volume":"4","author":"R Gmeiner","year":"1982","unstructured":"Gmeiner R, Ng CK. Metoprolol in the treatment and prophylaxis of paroxysmal reentrant supraventricular tachycardia. J Cardiovasc Pharmacol. 1982;4(1):5\u201313. https:\/\/doi.org\/10.1097\/00005344-198201000-00003.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"5","key":"828_CR49","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1055\/s-2008-1043903","volume":"210","author":"JP Pfammatter","year":"1998","unstructured":"Pfammatter JP, Weber JW, Stocker FP. Atenolol for preventing recurrence of atrioventricular reentry tachycardia in childhood. Klin Padiatr. 1998;210(5):358\u201362. https:\/\/doi.org\/10.1055\/s-2008-1043903.","journal-title":"Klin Padiatr"},{"issue":"Suppl 11","key":"828_CR50","doi-asserted-by":"publisher","first-page":"S167","DOI":"10.1097\/00005344-198511001-00030","volume":"8","author":"H Neuss","year":"1986","unstructured":"Neuss H, Conrad A, Mitrovic V, et al. Electrophysiologic effects of an acute beta-blockade induced by bisoprolol in patients with supraventricular tachycardia as assessed by His-bundle electrograms. J Cardiovasc Pharmacol. 1986;8(Suppl 11):S167\u201370. https:\/\/doi.org\/10.1097\/00005344-198511001-00030.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"20","key":"828_CR51","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJM197911153012003","volume":"301","author":"GJ Klein","year":"1979","unstructured":"Klein GJ, Bashore TM, Sellers TD, et al. Ventricular fibrillation in the Wolff\u2013Parkinson\u2013White syndrome. N Engl J Med. 1979;301(20):1080\u20135. https:\/\/doi.org\/10.1056\/NEJM197911153012003.","journal-title":"N Engl J Med"},{"issue":"9","key":"828_CR52","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1093\/europace\/eut082","volume":"15","author":"J Brugada","year":"2013","unstructured":"Brugada J, Blom N, Sarquella-Brugada G, et al. Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement. Europace. 2013;15(9):1337\u201382. https:\/\/doi.org\/10.1093\/europace\/eut082.","journal-title":"Europace"},{"issue":"3","key":"828_CR53","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/S0735-1097(10)80283-9","volume":"19","author":"AV Mehta","year":"1992","unstructured":"Mehta AV, Chidambaram B. Efficacy and safety of intravenous and oral nadolol for supraventricular tachycardia in children. J Am Coll Cardiol. 1992;19(3):630\u20135. https:\/\/doi.org\/10.1016\/S0735-1097(10)80283-9.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"828_CR54","doi-asserted-by":"publisher","first-page":"e937","DOI":"10.1161\/CIR.0000000000001226","volume":"149","author":"AS Batra","year":"2024","unstructured":"Batra AS, Silka MJ, Borquez A, et al. Pharmacological management of cardiac arrhythmias in the fetal and neonatal periods: a scientific statement from the American Heart Association: endorsed by the Pediatric & Congenital Electrophysiology Society (PACES). Circulation. 2024;149(10):e937\u201352. https:\/\/doi.org\/10.1161\/CIR.0000000000001226.","journal-title":"Circulation"},{"issue":"4","key":"828_CR55","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1161\/CIRCULATIONAHA.105.592410","volume":"115","author":"EP Walsh","year":"2007","unstructured":"Walsh EP, Cecchin F. Arrhythmias in adult patients with congenital heart disease. Circulation. 2007;115(4):534\u201345. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.592410.","journal-title":"Circulation"},{"issue":"9","key":"828_CR56","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1161\/CIRCULATIONAHA.109.928481","volume":"122","author":"P Khairy","year":"2010","unstructured":"Khairy P, Aboulhosn J, Gurvitz MZ, et al. Arrhythmia burden in adults with surgically repaired tetralogy of Fallot: a multi-institutional study. Circulation. 2010;122(9):868\u201375. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.928481.","journal-title":"Circulation"},{"issue":"6","key":"828_CR57","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s00246-007-9005-2","volume":"28","author":"BJ Deal","year":"2007","unstructured":"Deal BJ, Mavroudis C, Backer CL. Arrhythmia management in the Fontan patient. Pediatr Cardiol. 2007;28(6):448\u201356. https:\/\/doi.org\/10.1007\/s00246-007-9005-2.","journal-title":"Pediatr Cardiol"},{"issue":"15","key":"828_CR58","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.jacc.2015.07.065","volume":"66","author":"KN Pundi","year":"2015","unstructured":"Pundi KN, Johnson JN, Dearani JA, et al. 40-Year follow-up after the Fontan operation: long-term outcomes of 1,052 patients. J Am Coll Cardiol. 2015;66(15):1700\u201310. https:\/\/doi.org\/10.1016\/j.jacc.2015.07.065.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"828_CR59","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.jacc.2004.05.073","volume":"44","author":"JA Kammeraad","year":"2004","unstructured":"Kammeraad JA, van Deurzen CH, Sreeram N, et al. Predictors of sudden cardiac death after Mustard or Senning repair for transposition of the great arteries. J Am Coll Cardiol. 2004;44(5):1095\u2013102. https:\/\/doi.org\/10.1016\/j.jacc.2004.05.073.","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"828_CR60","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1161\/CIRCULATIONAHA.111.027763","volume":"124","author":"AC Zomer","year":"2011","unstructured":"Zomer AC, Verheugt CL, Vaartjes I, et al. Surgery in adults with congenital heart disease. Circulation. 2011;124(20):2195\u2013201. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.027763.","journal-title":"Circulation"},{"issue":"10","key":"828_CR61","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1016\/j.hrthm.2014.05.009","volume":"11","author":"P Khairy","year":"2014","unstructured":"Khairy P, Van Hare GF, Balaji S, et al. PACES\/HRS Expert Consensus Statement on the Recognition and Management of Arrhythmias in Adult Congenital Heart Disease: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology (ACC), the American Heart Association (AHA), the European Heart Rhythm Association (EHRA), the Canadian Heart Rhythm Society (CHRS), and the International Society for Adult Congenital Heart Disease (ISACHD). Heart Rhythm. 2014;11(10):e102\u201365. https:\/\/doi.org\/10.1016\/j.hrthm.2014.05.009.","journal-title":"Heart Rhythm"},{"issue":"6","key":"828_CR62","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/eurheartj\/ehaa554","volume":"42","author":"H Baumgartner","year":"2020","unstructured":"Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC guidelines for the management of adult congenital heart disease. Eur Heart J. 2020;42(6):563\u2013645. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa554.","journal-title":"Eur Heart J"},{"issue":"8","key":"828_CR63","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.amjcard.2005.11.041","volume":"97","author":"CK Silversides","year":"2006","unstructured":"Silversides CK, Harris L, Haberer K, et al. Recurrence rates of arrhythmias during pregnancy in women with previous tachyarrhythmia and impact on fetal and neonatal outcomes. Am J Cardiol. 2006;97(8):1206\u201312. https:\/\/doi.org\/10.1016\/j.amjcard.2005.11.041.","journal-title":"Am J Cardiol"},{"issue":"34","key":"828_CR64","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1093\/eurheartj\/ehy340","volume":"39","author":"V Regitz-Zagrosek","year":"2018","unstructured":"Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34):3165\u2013241. https:\/\/doi.org\/10.1093\/eurheartj\/ehy340.","journal-title":"Eur Heart J"},{"issue":"6752","key":"828_CR65","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1136\/bmj.301.6752.587","volume":"301","author":"L Butters","year":"1990","unstructured":"Butters L, Kennedy S, Rubin PC. Atenolol in essential hypertension during pregnancy. BMJ. 1990;301(6752):587\u20139. https:\/\/doi.org\/10.1136\/bmj.301.6752.587.","journal-title":"BMJ"},{"issue":"4","key":"828_CR66","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1161\/HYPERTENSIONAHA.106.075895","volume":"51","author":"T Podymow","year":"2008","unstructured":"Podymow T, August P. Update on the use of antihypertensive drugs in pregnancy. Hypertension. 2008;51(4):960\u20139. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.106.075895.","journal-title":"Hypertension"},{"issue":"16","key":"828_CR67","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.jacc.2009.05.066","volume":"54","author":"T Munzel","year":"2009","unstructured":"Munzel T, Gori T. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol. 2009;54(16):1491\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2009.05.066.","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"828_CR68","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1161\/hc4601.097997","volume":"104","author":"I Olivotto","year":"2001","unstructured":"Olivotto I, Cecchi F, Casey SA, et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001;104(21):2517\u201324. https:\/\/doi.org\/10.1161\/hc4601.097997.","journal-title":"Circulation"},{"issue":"3","key":"828_CR69","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001002","volume":"3","author":"KC Siontis","year":"2014","unstructured":"Siontis KC, Geske JB, Ong K, et al. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population. J Am Heart Assoc. 2014;3(3):e001002. https:\/\/doi.org\/10.1161\/JAHA.114.001002.","journal-title":"J Am Heart Assoc"},{"issue":"37","key":"828_CR70","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503\u2013626. https:\/\/doi.org\/10.1093\/eurheartj\/ehad194.","journal-title":"Eur Heart J"},{"issue":"39","key":"828_CR71","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","volume":"35","author":"PM Elliott","year":"2014","unstructured":"Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733\u201379. https:\/\/doi.org\/10.1093\/eurheartj\/ehu284.","journal-title":"Eur Heart J"},{"issue":"4","key":"828_CR72","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1056\/NEJM198501243120401","volume":"312","author":"HL Kennedy","year":"1985","unstructured":"Kennedy HL, Whitlock JA, Sprague MK, et al. Long-term follow-up of asymptomatic healthy subjects with frequent and complex ventricular ectopy. N Engl J Med. 1985;312(4):193\u20137. https:\/\/doi.org\/10.1056\/NEJM198501243120401.","journal-title":"N Engl J Med"},{"issue":"10","key":"828_CR73","doi-asserted-by":"publisher","first-page":"e385","DOI":"10.1161\/CIRCULATIONAHA.106.178233","volume":"114","author":"DP Zipes","year":"2006","unstructured":"Zipes DP, Camm AJ, Borggrefe M, et al. ACC\/AHA\/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology\/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114(10):e385-484. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.178233.","journal-title":"Circulation"},{"issue":"40","key":"828_CR74","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","volume":"43","author":"K Zeppenfeld","year":"2022","unstructured":"Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997\u20134126. https:\/\/doi.org\/10.1093\/eurheartj\/ehac262.","journal-title":"Eur Heart J"},{"issue":"7","key":"828_CR75","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.hrthm.2010.03.036","volume":"7","author":"TS Baman","year":"2010","unstructured":"Baman TS, Lange DC, Ilg KJ, et al. Relationship between burden of premature ventricular complexes and left ventricular function. Heart Rhythm. 2010;7(7):865\u20139. https:\/\/doi.org\/10.1016\/j.hrthm.2010.03.036.","journal-title":"Heart Rhythm"},{"issue":"1","key":"828_CR76","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0002-9149(83)90072-3","volume":"52","author":"CM Pratt","year":"1983","unstructured":"Pratt CM, Yepsen SC, Bloom MG, et al. Evaluation of metoprolol in suppressing complex ventricular arrhythmias. Am J Cardiol. 1983;52(1):73\u20138. https:\/\/doi.org\/10.1016\/0002-9149(83)90072-3.","journal-title":"Am J Cardiol"},{"issue":"3","key":"828_CR77","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jjcc.2017.01.008","volume":"70","author":"M Shinohara","year":"2017","unstructured":"Shinohara M, Fujino T, Koike H, et al. Assessment of a novel transdermal selective beta1-blocker, the bisoprolol patch, for treating frequent premature ventricular contractions in patients without structural heart disease. J Cardiol. 2017;70(3):212\u20139. https:\/\/doi.org\/10.1016\/j.jjcc.2017.01.008.","journal-title":"J Cardiol"},{"issue":"17","key":"828_CR78","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1007\/s40265-018-0999-y","volume":"78","author":"AFG Cicero","year":"2018","unstructured":"Cicero AFG, Kuwabara M, Borghi C. A critical review of nebivolol and its fixed-dose combinations in the treatment of hypertension. Drugs. 2018;78(17):1783\u201390. https:\/\/doi.org\/10.1007\/s40265-018-0999-y.","journal-title":"Drugs"},{"issue":"1","key":"828_CR79","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1161\/CIRCEP.111.963348","volume":"5","author":"GK Lee","year":"2012","unstructured":"Lee GK, Klarich KW, Grogan M, et al. Premature ventricular contraction-induced cardiomyopathy: a treatable condition. Circ Arrhythm Electrophysiol. 2012;5(1):229\u201336. https:\/\/doi.org\/10.1161\/CIRCEP.111.963348.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"25","key":"828_CR80","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1056\/NEJM199912163412503","volume":"341","author":"AE Buxton","year":"1999","unstructured":"Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999;341(25):1882\u201390. https:\/\/doi.org\/10.1056\/NEJM199912163412503.","journal-title":"N Engl J Med"},{"issue":"26","key":"828_CR81","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1056\/NEJM199612263352601","volume":"335","author":"AJ Moss","year":"1996","unstructured":"Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335(26):1933\u201340. https:\/\/doi.org\/10.1056\/NEJM199612263352601.","journal-title":"N Engl J Med"},{"issue":"4","key":"828_CR82","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00395-003-0398-7","volume":"98","author":"R Becker","year":"2003","unstructured":"Becker R, Haass M, Ick D, et al. Role of nonsustained ventricular tachycardia and programmed ventricular stimulation for risk stratification in patients with idiopathic dilated cardiomyopathy. Basic Res Cardiol. 2003;98(4):259\u201366. https:\/\/doi.org\/10.1007\/s00395-003-0398-7.","journal-title":"Basic Res Cardiol"},{"issue":"5","key":"828_CR83","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1161\/01.CIR.68.5.917","volume":"68","author":"AE Buxton","year":"1983","unstructured":"Buxton AE, Waxman HL, Marchlinski FE, et al. Right ventricular tachycardia: clinical and electrophysiologic characteristics. Circulation. 1983;68(5):917\u201327. https:\/\/doi.org\/10.1161\/01.CIR.68.5.917.","journal-title":"Circulation"},{"issue":"12","key":"828_CR84","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa013474","volume":"346","author":"AJ Moss","year":"2002","unstructured":"Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877\u201383. https:\/\/doi.org\/10.1056\/NEJMoa013474.","journal-title":"N Engl J Med"},{"issue":"3","key":"828_CR85","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1056\/NEJMoa043399","volume":"352","author":"GH Bardy","year":"2005","unstructured":"Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225\u201337. https:\/\/doi.org\/10.1056\/NEJMoa043399.","journal-title":"N Engl J Med"},{"issue":"10","key":"828_CR86","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1016\/j.hrthm.2017.10.035","volume":"15","author":"SM Al-Khatib","year":"2018","unstructured":"Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. 2018;15(10):e190\u2013252. https:\/\/doi.org\/10.1016\/j.hrthm.2017.10.035.","journal-title":"Heart Rhythm"},{"issue":"5","key":"828_CR87","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.amjcard.2005.04.046","volume":"96","author":"WN Brodine","year":"2005","unstructured":"Brodine WN, Tung RT, Lee JK, et al. Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II). Am J Cardiol. 2005;96(5):691\u20135. https:\/\/doi.org\/10.1016\/j.amjcard.2005.04.046.","journal-title":"Am J Cardiol"},{"key":"828_CR88","doi-asserted-by":"publisher","unstructured":"MERIT-HF Study Group. Effect of metoprolol CR\/XL in chronic heart failure: metoprolol CR\/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353(9169):2001\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(99)04440-2.","DOI":"10.1016\/S0140-6736(99)04440-2"},{"key":"828_CR89","doi-asserted-by":"publisher","unstructured":"CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9\u201313. https:\/\/doi.org\/10.1016\/S0140-6736(98)11181-9","DOI":"10.1016\/S0140-6736(98)11181-9"},{"issue":"9377","key":"828_CR90","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0140-6736(03)13800-7","volume":"362","author":"PA Poole-Wilson","year":"2003","unstructured":"Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7\u201313. https:\/\/doi.org\/10.1016\/S0140-6736(03)13800-7.","journal-title":"Lancet"},{"issue":"6","key":"828_CR91","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.tcm.2015.01.011","volume":"25","author":"BB Lerman","year":"2015","unstructured":"Lerman BB. Outflow tract ventricular arrhythmias: an update. Trends Cardiovasc Med. 2015;25(6):550\u20138. https:\/\/doi.org\/10.1016\/j.tcm.2015.01.011.","journal-title":"Trends Cardiovasc Med"},{"issue":"9","key":"828_CR92","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S0195-668X(02)00654-1","volume":"24","author":"D O'Donnell","year":"2003","unstructured":"O\u2019Donnell D, Cox D, Bourke J, et al. Clinical and electrophysiological differences between patients with arrhythmogenic right ventricular dysplasia and right ventricular outflow tract tachycardia. Eur Heart J. 2003;24(9):801\u201310. https:\/\/doi.org\/10.1016\/S0195-668X(02)00654-1.","journal-title":"Eur Heart J"},{"issue":"20","key":"828_CR93","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1016\/j.jacc.2007.01.085","volume":"49","author":"RJ Kim","year":"2007","unstructured":"Kim RJ, Iwai S, Markowitz SM, et al. Clinical and electrophysiological spectrum of idiopathic ventricular outflow tract arrhythmias. J Am Coll Cardiol. 2007;49(20):2035\u201343. https:\/\/doi.org\/10.1016\/j.jacc.2007.01.085.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"828_CR94","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1136\/hrt.2004.033795","volume":"91","author":"A Farzaneh-Far","year":"2005","unstructured":"Farzaneh-Far A, Lerman BB. Idiopathic ventricular outflow tract tachycardia. Heart. 2005;91(2):136\u20138. https:\/\/doi.org\/10.1136\/hrt.2004.033795.","journal-title":"Heart"},{"issue":"6","key":"828_CR95","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1136\/hrt.46.6.679","volume":"46","author":"B Belhassen","year":"1981","unstructured":"Belhassen B, Rotmensch HH, Laniado S. Response of recurrent sustained ventricular tachycardia to verapamil. Br Heart J. 1981;46(6):679\u201382. https:\/\/doi.org\/10.1136\/hrt.46.6.679.","journal-title":"Br Heart J"},{"key":"828_CR96","doi-asserted-by":"publisher","unstructured":"Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA. 1982;247(12):1707\u201314. https:\/\/doi.org\/10.1001\/jama.1982.03320370021023","DOI":"10.1001\/jama.1982.03320370021023"},{"issue":"14","key":"828_CR97","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1056\/NEJM198104023041401","volume":"304","author":"Norwegian Multicenter Study Group","year":"1981","unstructured":"Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981;304(14):801\u20137. https:\/\/doi.org\/10.1056\/NEJM198104023041401.","journal-title":"N Engl J Med"},{"issue":"9266","key":"828_CR98","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","volume":"357","author":"HJ Dargie","year":"2001","unstructured":"Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357(9266):1385\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(00)04560-8.","journal-title":"Lancet"},{"issue":"24","key":"828_CR99","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJM199906173402402","volume":"340","author":"A Pacifico","year":"1999","unstructured":"Pacifico A, Hohnloser SH, Williams JH, et al. Prevention of implantable-defibrillator shocks by treatment with sotalol. N Engl J Med. 1999;340(24):1855\u201362. https:\/\/doi.org\/10.1056\/NEJM199906173402402.","journal-title":"N Engl J Med"},{"issue":"2","key":"828_CR100","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jama.295.2.165","volume":"295","author":"SJ Connolly","year":"2006","unstructured":"Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006;295(2):165\u201371. https:\/\/doi.org\/10.1001\/jama.295.2.165.","journal-title":"JAMA"},{"issue":"5","key":"828_CR101","doi-asserted-by":"publisher","first-page":"E9","DOI":"10.1067\/mhj.2002.126114","volume":"144","author":"RG Mitchell","year":"2002","unstructured":"Mitchell RG, Stoddard MF, Ben-Yehuda O, et al. Esmolol in acute ischemic syndromes. Am Heart J. 2002;144(5):E9. https:\/\/doi.org\/10.1067\/mhj.2002.126114.","journal-title":"Am Heart J"},{"issue":"23","key":"828_CR102","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1161\/01.CIR.0000100721.52503.85","volume":"108","author":"W Grimm","year":"2003","unstructured":"Grimm W, Christ M, Bach J, et al. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg Cardiomyopathy Study. Circulation. 2003;108(23):2883\u201391. https:\/\/doi.org\/10.1161\/01.CIR.0000100721.52503.85.","journal-title":"Circulation"},{"issue":"36","key":"828_CR103","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368.","journal-title":"Eur Heart J"},{"issue":"21","key":"828_CR104","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1056\/NEJMoa033088","volume":"350","author":"A Kadish","year":"2004","unstructured":"Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350(21):2151\u20138. https:\/\/doi.org\/10.1056\/NEJMoa033088.","journal-title":"N Engl J Med"},{"issue":"2","key":"828_CR105","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1056\/NEJM199507133330201","volume":"333","author":"SN Singh","year":"1995","unstructured":"Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med. 1995;333(2):77\u201382. https:\/\/doi.org\/10.1056\/NEJM199507133330201.","journal-title":"N Engl J Med"},{"issue":"1","key":"828_CR106","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/CCM.0b013e3181fd6ad7","volume":"39","author":"JP Piccini","year":"2011","unstructured":"Piccini JP, Schulte PJ, Pieper KS, et al. Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction. Crit Care Med. 2011;39(1):78\u201383. https:\/\/doi.org\/10.1097\/CCM.0b013e3181fd6ad7.","journal-title":"Crit Care Med"},{"issue":"8","key":"828_CR107","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.109.192704","volume":"121","author":"BJ Drew","year":"2010","unstructured":"Drew BJ, Ackerman MJ, Funk M, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation. 2010;121(8):1047\u201360. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.192704.","journal-title":"Circulation"},{"issue":"1","key":"828_CR108","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1161\/01.CIR.0000020013.73106.D8","volume":"106","author":"SG Priori","year":"2002","unstructured":"Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2002;106(1):69\u201374. https:\/\/doi.org\/10.1161\/01.CIR.0000020013.73106.D8.","journal-title":"Circulation"},{"issue":"18 Suppl 2","key":"828_CR109","doi-asserted-by":"publisher","first-page":"S444","DOI":"10.1161\/CIR.0000000000000261","volume":"132","author":"MS Link","year":"2015","unstructured":"Link MS, Berkow LC, Kudenchuk PJ, et al. Part 7: adult advanced cardiovascular life support: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015;132(18 Suppl 2):S444\u201364. https:\/\/doi.org\/10.1161\/CIR.0000000000000261.","journal-title":"Circulation"},{"issue":"7","key":"828_CR110","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1161\/01.CIR.102.7.742","volume":"102","author":"K Nademanee","year":"2000","unstructured":"Nademanee K, Taylor R, Bailey WE, et al. Treating electrical storm: sympathetic blockade versus advanced cardiac life support-guided therapy. Circulation. 2000;102(7):742\u20137. https:\/\/doi.org\/10.1161\/01.CIR.102.7.742.","journal-title":"Circulation"},{"issue":"17","key":"828_CR111","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1016\/j.jacc.2018.02.056","volume":"71","author":"S Chatzidou","year":"2018","unstructured":"Chatzidou S, Kontogiannis C, Tsilimigras DI, et al. Propranolol versus metoprolol for treatment of electrical storm in patients with implantable cardioverter-defibrillator. J Am Coll Cardiol. 2018;71(17):1897\u2013906. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.056.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"828_CR112","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1253\/circj.CJ-09-0772","volume":"74","author":"Y Miwa","year":"2010","unstructured":"Miwa Y, Ikeda T, Mera H, et al. Effects of landiolol, an ultra-short-acting beta1-selective blocker, on electrical storm refractory to class III antiarrhythmic drugs. Circ J. 2010;74(5):856\u201363. https:\/\/doi.org\/10.1253\/circj.CJ-09-0772.","journal-title":"Circ J"},{"issue":"21","key":"828_CR113","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1161\/CIRCULATIONAHA.109.929703","volume":"121","author":"T Bourke","year":"2010","unstructured":"Bourke T, Vaseghi M, Michowitz Y, et al. Neuraxial modulation for refractory ventricular arrhythmias: value of thoracic epidural anesthesia and surgical left cardiac sympathetic denervation. Circulation. 2010;121(21):2255\u201362. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.929703.","journal-title":"Circulation"},{"issue":"15","key":"828_CR114","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1161\/01.CIR.0000125523.14403.1E","volume":"109","author":"PJ Schwartz","year":"2004","unstructured":"Schwartz PJ, Priori SG, Cerrone M, et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation. 2004;109(15):1826\u201333. https:\/\/doi.org\/10.1161\/01.CIR.0000125523.14403.1E.","journal-title":"Circulation"},{"key":"828_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.resuscitation.2024.110273","volume":"201","author":"G Gelbenegger","year":"2024","unstructured":"Gelbenegger G, Jilma B, Horvath LC, et al. Landiolol for refractory ventricular fibrillation in out-of-hospital cardiac arrest: a randomized, double-blind, placebo-controlled, pilot trial. Resuscitation. 2024;201:110273. https:\/\/doi.org\/10.1016\/j.resuscitation.2024.110273.","journal-title":"Resuscitation"},{"issue":"24","key":"828_CR116","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1053\/euhj.2000.2476","volume":"21","author":"SJ Connolly","year":"2000","unstructured":"Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies Antiarrhythmics vs Implantable Defibrillator study Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. 2000;21(24):2071\u20138. https:\/\/doi.org\/10.1053\/euhj.2000.2476.","journal-title":"Eur Heart J"},{"issue":"8","key":"828_CR117","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1161\/01.CIR.0000027564.55739.B1","volume":"106","author":"M Haissaguerre","year":"2002","unstructured":"Haissaguerre M, Shoda M, Jais P, et al. Mapping and ablation of idiopathic ventricular fibrillation. Circulation. 2002;106(8):962\u20137. https:\/\/doi.org\/10.1161\/01.CIR.0000027564.55739.B1.","journal-title":"Circulation"},{"issue":"2","key":"828_CR118","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1161\/01.CIR.103.2.196","volume":"103","author":"SG Priori","year":"2001","unstructured":"Priori SG, Napolitano C, Tiso N, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation. 2001;103(2):196\u2013200. https:\/\/doi.org\/10.1161\/01.CIR.103.2.196.","journal-title":"Circulation"},{"issue":"6","key":"828_CR119","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1086\/324565","volume":"69","author":"H Lahat","year":"2001","unstructured":"Lahat H, Pras E, Olender T, et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet. 2001;69(6):1378\u201384. https:\/\/doi.org\/10.1086\/324565.","journal-title":"Am J Hum Genet"},{"issue":"12","key":"828_CR120","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/j.hrthm.2013.05.014","volume":"10","author":"SG Priori","year":"2013","unstructured":"Priori SG, Wilde AA, Horie M, et al. HRS\/EHRA\/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013;10(12):1932\u201363. https:\/\/doi.org\/10.1016\/j.hrthm.2013.05.014.","journal-title":"Heart Rhythm"},{"issue":"18","key":"828_CR121","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1161\/CIRCULATIONAHA.108.829267","volume":"119","author":"M Hayashi","year":"2009","unstructured":"Hayashi M, Denjoy I, Extramiana F, et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation. 2009;119(18):2426\u201334. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.829267.","journal-title":"Circulation"},{"issue":"3","key":"828_CR122","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1161\/CIRCEP.114.002217","volume":"8","author":"TM Roston","year":"2015","unstructured":"Roston TM, Vinocur JM, Maginot KR, et al. Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry. Circ Arrhythm Electrophysiol. 2015;8(3):633\u201342. https:\/\/doi.org\/10.1161\/CIRCEP.114.002217.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"5","key":"828_CR123","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1001\/jamacardio.2022.0219","volume":"7","author":"A Mazzanti","year":"2022","unstructured":"Mazzanti A, Kukavica D, Trancuccio A, et al. Outcomes of patients with catecholaminergic polymorphic ventricular tachycardia treated with beta-blockers. JAMA Cardiol. 2022;7(5):504\u201312. https:\/\/doi.org\/10.1001\/jamacardio.2022.0219.","journal-title":"JAMA Cardiol."},{"issue":"2","key":"828_CR124","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.hrthm.2015.09.029","volume":"13","author":"IS Leren","year":"2016","unstructured":"Leren IS, Saberniak J, Majid E, et al. Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with beta1-selective beta-blockers in patients with catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2016;13(2):433\u201340. https:\/\/doi.org\/10.1016\/j.hrthm.2015.09.029.","journal-title":"Heart Rhythm"},{"issue":"4","key":"828_CR125","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nm.1942","volume":"15","author":"H Watanabe","year":"2009","unstructured":"Watanabe H, Chopra N, Laver D, et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med. 2009;15(4):380\u20133. https:\/\/doi.org\/10.1038\/nm.1942.","journal-title":"Nat Med"},{"issue":"1","key":"828_CR126","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.hrthm.2013.10.027","volume":"11","author":"F Roses-Noguer","year":"2014","unstructured":"Roses-Noguer F, Jarman JW, Clague JR, et al. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2014;11(1):58\u201366. https:\/\/doi.org\/10.1016\/j.hrthm.2013.10.027.","journal-title":"Heart Rhythm"},{"issue":"22","key":"828_CR127","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1016\/j.jacc.2011.01.026","volume":"57","author":"C van der Werf","year":"2011","unstructured":"van der Werf C, Kannankeril PJ, Sacher F, et al. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol. 2011;57(22):2244\u201354. https:\/\/doi.org\/10.1016\/j.jacc.2011.01.026.","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"828_CR128","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1161\/CIRCULATIONAHA.106.665406","volume":"115","author":"AJ Moss","year":"2007","unstructured":"Moss AJ, Shimizu W, Wilde AA, et al. Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation. 2007;115(19):2481\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.665406.","journal-title":"Circulation"},{"issue":"1","key":"828_CR129","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jacc.2010.07.038","volume":"57","author":"I Goldenberg","year":"2011","unstructured":"Goldenberg I, Horr S, Moss AJ, et al. Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. J Am Coll Cardiol. 2011;57(1):51\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2010.07.038.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"828_CR130","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/S0735-1097(99)00582-3","volume":"35","author":"W Shimizu","year":"2000","unstructured":"Shimizu W, Antzelevitch C. Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome. J Am Coll Cardiol. 2000;35(3):778\u201386. https:\/\/doi.org\/10.1016\/S0735-1097(99)00582-3.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"828_CR131","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1001\/jama.292.11.1341","volume":"292","author":"SG Priori","year":"2004","unstructured":"Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA. 2004;292(11):1341\u20134. https:\/\/doi.org\/10.1001\/jama.292.11.1341.","journal-title":"JAMA"},{"issue":"1","key":"828_CR132","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1365-2796.2005.01583.x","volume":"259","author":"PJ Schwartz","year":"2006","unstructured":"Schwartz PJ. The congenital long QT syndromes from genotype to phenotype: clinical implications. J Intern Med. 2006;259(1):39\u201347. https:\/\/doi.org\/10.1111\/j.1365-2796.2005.01583.x.","journal-title":"J Intern Med"},{"issue":"9","key":"828_CR133","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.jacc.2015.12.033","volume":"67","author":"A Mazzanti","year":"2016","unstructured":"Mazzanti A, Maragna R, Faragli A, et al. Gene-specific therapy with mexiletine reduces arrhythmic events in patients with long QT syndrome type 3. J Am Coll Cardiol. 2016;67(9):1053\u20138. https:\/\/doi.org\/10.1016\/j.jacc.2015.12.033.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"828_CR134","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1161\/01.CIR.103.1.89","volume":"103","author":"PJ Schwartz","year":"2001","unstructured":"Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype\u2013phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. 2001;103(1):89\u201395. https:\/\/doi.org\/10.1161\/01.CIR.103.1.89.","journal-title":"Circulation"},{"issue":"22","key":"828_CR135","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/j.jacc.2009.08.028","volume":"54","author":"W Shimizu","year":"2009","unstructured":"Shimizu W, Moss AJ, Wilde AA, et al. Genotype\u2013phenotype aspects of type 2 long QT syndrome. J Am Coll Cardiol. 2009;54(22):2052\u201362. https:\/\/doi.org\/10.1016\/j.jacc.2009.08.028.","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"828_CR136","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1016\/j.jacc.2012.07.046","volume":"60","author":"P Chockalingam","year":"2012","unstructured":"Chockalingam P, Crotti L, Girardengo G, et al. Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol. J Am Coll Cardiol. 2012;60(20):2092\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2012.07.046.","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"828_CR137","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1161\/CIRCULATIONAHA.108.840827","volume":"121","author":"FI Marcus","year":"2010","unstructured":"Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy\/dysplasia: proposed modification of the task force criteria. Circulation. 2010;121(13):1533\u201341. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.840827.","journal-title":"Circulation"},{"issue":"1","key":"828_CR138","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1056\/NEJMra1509267","volume":"376","author":"D Corrado","year":"2017","unstructured":"Corrado D, Link MS, Calkins H. Arrhythmogenic right ventricular cardiomyopathy. N Engl J Med. 2017;376(1):61\u201372. https:\/\/doi.org\/10.1056\/NEJMra1509267.","journal-title":"N Engl J Med"},{"issue":"11","key":"828_CR139","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1016\/j.hrthm.2019.05.007","volume":"16","author":"JA Towbin","year":"2019","unstructured":"Towbin JA, McKenna WJ, Abrams DJ, et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm. 2019;16(11):e301\u201372. https:\/\/doi.org\/10.1016\/j.hrthm.2019.05.007.","journal-title":"Heart Rhythm"},{"issue":"7","key":"828_CR140","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.jacc.2009.04.052","volume":"54","author":"GM Marcus","year":"2009","unstructured":"Marcus GM, Glidden DV, Polonsky B, et al. Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry. J Am Coll Cardiol. 2009;54(7):609\u201315. https:\/\/doi.org\/10.1016\/j.jacc.2009.04.052.","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"828_CR141","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1161\/01.CIR.0000103130.33451.D2","volume":"108","author":"D Corrado","year":"2003","unstructured":"Corrado D, Leoni L, Link MS, et al. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy\/dysplasia. Circulation. 2003;108(25):3084\u201391. https:\/\/doi.org\/10.1161\/01.CIR.0000103130.33451.D2.","journal-title":"Circulation"},{"issue":"6","key":"828_CR142","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/0735-1097(92)90253-J","volume":"20","author":"P Brugada","year":"1992","unstructured":"Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol. 1992;20(6):1391\u20136. https:\/\/doi.org\/10.1016\/0735-1097(92)90253-J.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"828_CR143","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jacc.2011.08.064","volume":"59","author":"SG Priori","year":"2012","unstructured":"Priori SG, Gasparini M, Napolitano C, et al. Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry. J Am Coll Cardiol. 2012;59(1):37\u201345. https:\/\/doi.org\/10.1016\/j.jacc.2011.08.064.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"828_CR144","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.109.887026","volume":"121","author":"V Probst","year":"2010","unstructured":"Probst V, Veltmann C, Eckardt L, et al. Long-term prognosis of patients diagnosed with Brugada syndrome: results from the FINGER Brugada Syndrome Registry. Circulation. 2010;121(5):635\u201343. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.887026.","journal-title":"Circulation"},{"issue":"19","key":"828_CR145","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1161\/01.CIR.0000034169.45752.4A","volume":"106","author":"AA Wilde","year":"2002","unstructured":"Wilde AA, Antzelevitch C, Borggrefe M, et al. Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation. 2002;106(19):2514\u20139. https:\/\/doi.org\/10.1161\/01.CIR.0000034169.45752.4A.","journal-title":"Circulation"},{"issue":"13","key":"828_CR146","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1161\/01.CIR.0000143159.30585.90","volume":"110","author":"B Belhassen","year":"2004","unstructured":"Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation. 2004;110(13):1731\u20137. https:\/\/doi.org\/10.1161\/01.CIR.0000143159.30585.90.","journal-title":"Circulation"},{"issue":"1","key":"828_CR147","first-page":"25","volume":"5","author":"P Maury","year":"2005","unstructured":"Maury P, Hocini M, Haissaguerre M. Electrical storms in Brugada syndrome: review of pharmacologic and ablative therapeutic options. Indian Pacing Electrophysiol J. 2005;5(1):25\u201334.","journal-title":"Indian Pacing Electrophysiol J."},{"issue":"8","key":"828_CR148","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1161\/01.CIR.102.8.858","volume":"102","author":"BJ Maron","year":"2000","unstructured":"Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation. 2000;102(8):858\u201364. https:\/\/doi.org\/10.1161\/01.CIR.102.8.858.","journal-title":"Circulation"},{"issue":"10","key":"828_CR149","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1001\/jama.287.10.1308","volume":"287","author":"BJ Maron","year":"2002","unstructured":"Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002;287(10):1308\u201320. https:\/\/doi.org\/10.1001\/jama.287.10.1308.","journal-title":"JAMA"},{"issue":"4","key":"828_CR150","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1161\/CIRCHEARTFAILURE.112.000122","volume":"6","author":"MV Sherrid","year":"2013","unstructured":"Sherrid MV, Shetty A, Winson G, et al. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with beta-blockade or verapamil. Circ Heart Fail. 2013;6(4):694\u2013702. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.112.000122.","journal-title":"Circ Heart Fail"},{"issue":"25","key":"828_CR151","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","volume":"76","author":"SR Ommen","year":"2020","unstructured":"Ommen SR, Mital S, Burke MA, et al. 2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol. 2020;76(25):e159\u2013240. https:\/\/doi.org\/10.1016\/j.jacc.2020.08.045.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"828_CR152","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1136\/hrt.2006.099416","volume":"93","author":"P Melacini","year":"2007","unstructured":"Melacini P, Maron BJ, Bobbo F, et al. Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy. Heart. 2007;93(6):708\u201310. https:\/\/doi.org\/10.1136\/hrt.2006.099416.","journal-title":"Heart"},{"issue":"4","key":"828_CR153","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1001\/jama.298.4.405","volume":"298","author":"BJ Maron","year":"2007","unstructured":"Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007;298(4):405\u201312. https:\/\/doi.org\/10.1001\/jama.298.4.405.","journal-title":"JAMA"},{"issue":"10253","key":"828_CR154","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759\u201369. https:\/\/doi.org\/10.1016\/S0140-6736(20)31792-X.","journal-title":"Lancet"},{"issue":"20","key":"828_CR155","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","volume":"390","author":"MS Maron","year":"2024","unstructured":"Maron MS, Masri A, Nassif ME. Aficamten for symptomatic obstructive hypertrophic cardiomyopathy. N Engl J Med. 2024;390(20):1849\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2401424.","journal-title":"N Engl J Med"},{"issue":"23","key":"828_CR156","doi-asserted-by":"publisher","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","volume":"149","author":"SR Ommen","year":"2024","unstructured":"Ommen SR, Ho CY, Asif IM. 2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy. Circulation. 2024;149(23):e1239\u2013311. https:\/\/doi.org\/10.1161\/CIR.0000000000001250.","journal-title":"Circulation"},{"issue":"8","key":"828_CR157","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","volume":"45","author":"MV Sherrid","year":"2005","unstructured":"Sherrid MV, Barac I, McKenna WJ. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45(8):1251\u20138. https:\/\/doi.org\/10.1016\/j.jacc.2005.01.012.","journal-title":"J Am Coll Cardiol"},{"issue":"9234","key":"828_CR158","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S0140-6736(00)02714-8","volume":"356","author":"MA Gatzoulis","year":"2000","unstructured":"Gatzoulis MA, Balaji S, Webber SA, et al. Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study. Lancet. 2000;356(9234):975\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(00)02714-8.","journal-title":"Lancet"},{"issue":"22","key":"828_CR159","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1161\/CIRCULATIONAHA.115.017202","volume":"132","author":"GP Diller","year":"2015","unstructured":"Diller GP, Kempny A, Alonso-Gonzalez R, et al. Survival prospects and circumstances of death in contemporary adult congenital heart disease patients under follow-up at a large tertiary centre. Circulation. 2015;132(22):2118\u201325. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.017202.","journal-title":"Circulation"},{"issue":"23","key":"828_CR160","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/j.jacc.2008.10.001","volume":"52","author":"CA Warnes","year":"2008","unstructured":"Warnes CA, Williams RG, Bashore TM, et al. ACC\/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease). Developed in collaboration with the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;52(23):e143\u2013263. https:\/\/doi.org\/10.1016\/j.jacc.2008.10.001.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"828_CR161","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/S0735-1097(02)02344-6","volume":"40","author":"A Ghai","year":"2002","unstructured":"Ghai A, Silversides C, Harris L, et al. Left ventricular dysfunction is a risk factor for sudden cardiac death in adults late after repair of tetralogy of Fallot. J Am Coll Cardiol. 2002;40(9):1675\u201380. https:\/\/doi.org\/10.1016\/S0735-1097(02)02344-6.","journal-title":"J Am Coll Cardiol"},{"issue":"4 Suppl","key":"828_CR162","doi-asserted-by":"publisher","first-page":"S106","DOI":"10.1016\/S0003-4975(99)01265-5","volume":"69","author":"JA Dearani","year":"2000","unstructured":"Dearani JA, Danielson GK. Congenital heart surgery nomenclature and database project: Ebstein\u201ds anomaly and tricuspid valve disease. Ann Thorac Surg. 2000;69(4 Suppl):S106\u201317. https:\/\/doi.org\/10.1016\/S0003-4975(99)01265-5.","journal-title":"Ann Thorac Surg"},{"issue":"2","key":"828_CR163","doi-asserted-by":"publisher","first-page":"xv","DOI":"10.1016\/j.ccep.2017.04.001","volume":"9","author":"S Balaji","year":"2017","unstructured":"Balaji S, Mandapati R, Shivkumar K. Cardiac arrhythmias in adults with congenital heart disease. Card Electrophysiol Clin. 2017;9(2):xv\u2013xvi. https:\/\/doi.org\/10.1016\/j.ccep.2017.04.001.","journal-title":"Card Electrophysiol Clin"},{"issue":"12","key":"828_CR164","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11936-015-0418-6","volume":"17","author":"I Lindsay","year":"2015","unstructured":"Lindsay I, Moore JP. Cardiac arrhythmias in adults with congenital heart disease: scope, specific problems, and management. Curr Treat Options Cardiovasc Med. 2015;17(12):56. https:\/\/doi.org\/10.1007\/s11936-015-0418-6.","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"17","key":"828_CR165","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1161\/CIRCULATIONAHA.107.701243","volume":"117","author":"I Goldenberg","year":"2008","unstructured":"Goldenberg I, Moss AJ, Peterson DR, et al. Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome. Circulation. 2008;117(17):2184\u201391. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.701243.","journal-title":"Circulation"},{"issue":"1","key":"828_CR166","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrcardio.2010.162","volume":"8","author":"JL Fleg","year":"2011","unstructured":"Fleg JL, Aronow WS, Frishman WH. Cardiovascular drug therapy in the elderly: benefits and challenges. Nat Rev Cardiol. 2011;8(1):13\u201328. https:\/\/doi.org\/10.1038\/nrcardio.2010.162.","journal-title":"Nat Rev Cardiol"},{"issue":"10","key":"828_CR167","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.jacc.2006.09.054","volume":"49","author":"R Seth","year":"2007","unstructured":"Seth R, Moss AJ, McNitt S, et al. Long QT syndrome and pregnancy. J Am Coll Cardiol. 2007;49(10):1092\u20138. https:\/\/doi.org\/10.1016\/j.jacc.2006.09.054.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"828_CR168","doi-asserted-by":"publisher","first-page":"665","DOI":"10.7326\/M18-0338","volume":"169","author":"BT Bateman","year":"2018","unstructured":"Bateman BT, Heide-Jorgensen U, Einarsdottir K, et al. Beta-blocker use in pregnancy and the risk for congenital malformations: an international cohort study. Ann Intern Med. 2018;169(10):665\u201373. https:\/\/doi.org\/10.7326\/M18-0338.","journal-title":"Ann Intern Med"},{"issue":"10","key":"828_CR169","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1016\/j.hrthm.2023.05.017","volume":"20","author":"JA Joglar","year":"2023","unstructured":"Joglar JA, Kapa S, Saarel EV, et al. 2023 HRS expert consensus statement on the management of arrhythmias during pregnancy. Heart Rhythm. 2023;20(10):e175\u2013264. https:\/\/doi.org\/10.1016\/j.hrthm.2023.05.017.","journal-title":"Heart Rhythm"},{"issue":"4","key":"828_CR170","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1177\/1074248413484986","volume":"18","author":"WH Frishman","year":"2013","unstructured":"Frishman WH. beta-Adrenergic blockade in cardiovascular disease. J Cardiovasc Pharmacol Ther. 2013;18(4):310\u20139. https:\/\/doi.org\/10.1177\/1074248413484986.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"17","key":"828_CR171","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1016\/j.jacc.2010.01.024","volume":"55","author":"A Jabbour","year":"2010","unstructured":"Jabbour A, Macdonald PS, Keogh AM, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol. 2010;55(17):1780\u20137. https:\/\/doi.org\/10.1016\/j.jacc.2010.01.024.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"828_CR172","doi-asserted-by":"publisher","first-page":"11465","DOI":"10.1038\/s41598-019-47967-y","volume":"9","author":"M Sessa","year":"2019","unstructured":"Sessa M, Mascolo A, Rasmussen DB, et al. Beta-blocker choice and exchangeability in patients with heart failure and chronic obstructive pulmonary disease: an Italian register-based cohort study. Sci Rep. 2019;9(1):11465. https:\/\/doi.org\/10.1038\/s41598-019-47967-y.","journal-title":"Sci Rep"},{"key":"828_CR173","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejim.2021.03.035","volume":"88","author":"S Paolillo","year":"2021","unstructured":"Paolillo S, Dell\u2019Aversana S, Esposito I, et al. The use of beta-blockers in patients with heart failure and comorbidities: doubts, certainties and unsolved issues. Eur J Intern Med. 2021;88:9\u201314. https:\/\/doi.org\/10.1016\/j.ejim.2021.03.035.","journal-title":"Eur J Intern Med"},{"issue":"3","key":"828_CR174","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1001\/jama.288.3.351","volume":"288","author":"DT Ko","year":"2002","unstructured":"Ko DT, Hebert PR, Coffey CS, et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002;288(3):351\u20137. https:\/\/doi.org\/10.1001\/jama.288.3.351.","journal-title":"JAMA"},{"issue":"5","key":"828_CR175","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/0002-8703(87)90933-1","volume":"113","author":"WH Frishman","year":"1987","unstructured":"Frishman WH. Clinical differences between beta-adrenergic blocking agents: implications for therapeutic substitution. Am Heart J. 1987;113(5):1190\u20138. https:\/\/doi.org\/10.1016\/0002-8703(87)90933-1.","journal-title":"Am Heart J"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-026-00828-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-026-00828-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-026-00828-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:46:50Z","timestamp":1790002010000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-026-00828-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":175,"alternative-id":["828"],"URL":"https:\/\/doi.org\/10.1007\/s40256-026-00828-2","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"18 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Lucian Muresan, Gabriel Cismaru, Stefan Lucian Popa, Radu Rosu, Gabriel Gusetu, Mihai Puiu, Razvan Olimpiu Mada, Crina Muresan, Ronan Le Bouar, Serban Schiau, Charline Daval, Jacques Levy, and Raphael Pedro Martins declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Lucian Muresan: conceptualization, investigation, and writing of the original draft. Gabriel Cismaru, Stefan Lucian Popa, Radu Rosu, and Gabriel Gusetu: data curation, investigation, and literature review. Mihai Puiu, Razvan Olimpiu Mada, Crina Muresan, and Ronan Le Bouar: formal analysis, data curation, study selection, and writing of the original draft. Serban Schiau and Charline Daval: writing, and review and editing of successive drafts. Jacques Levy: critical review, validation, and supervision. Raphael Pedro Martins: critical review and editing of the final version, supervision, and guarantor of the work. All authors have read and approved the final version of this manuscript.","order":2,"name":"Ethics","label":"Authors' contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data sharing not applicable to this article as no datasets were generated for it.","order":3,"name":"Ethics","label":"Data availability statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}